BI
Bilcare Ltd (BI)
₹80.38
Mkt cap
₹182 Cr
P/E ratio
4.99
P/B
1.06
Div yield
0.00%
ROE
1.39%
ROCE
7.06%
EPS (TTM)
₹16.11
Book value
₹76
52W range
35–113
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
NSE BIBSE 526853
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−28.87% from high₹80
₹35+129.66% from low₹113
Current
₹80.38
Prev close
₹82.07
Day
−2.06%
Price performance
1D
−2.06%
1W
−0.04%
1M
−7.69%
3M
−12.31%
6M
+28.38%
1Y
—
YTD
+26.19%
Financials
Revenue, profit & margin
P/E ratio
5.0×
BI is 80% below the sector median of 24.4×
BI5.0×
Sector median24.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 189.92 | 174.94 | 200.07 | 194.14 | 201.74 | 198.13 | 194.03 | 186.36 | 178.20 | 181.32 | 187.66 | 225.86 | 248.43 | |
| YoY Sales growth | -25.24% | -28.85% | -14.35% | +6.52% | +6.22% | +13.26% | -3.02% | -4.01% | -11.67% | -8.48% | -3.28% | +21.20% | +39.41% | |
| Expenses | 173.22 | 157.69 | 208.33 | 175.20 | 194.09 | 187.47 | 186.35 | 175.29 | 174.78 | 168.31 | 170.73 | 188.84 | 226.12 | |
| Operating Profit | 16.70 | 17.25 | -8.26 | 18.94 | 7.65 | 10.66 | 7.68 | 11.07 | 3.42 | 13.01 | 16.93 | 37.02 | 22.31 | |
| OPM % | 8.79% | 9.86% | -4.13% | 9.76% | 3.79% | 5.38% | 3.96% | 5.94% | 1.92% | 7.18% | 9.02% | 16.39% | 8.98% | |
| Other Income | 0.56 | 3.76 | 8.82 | 3.74 | -6.02 | -6.47 | 21.16 | 6.08 | 4.32 | 3.34 | 12.46 | 0.01 | 3.53 | |
| Interest | 19.66 | 20.54 | 22.59 | 20.85 | 23.68 | 19.48 | 18.68 | 18.55 | 19.06 | 17.04 | 17.69 | 18.08 | 19.73 | |
| Depreciation | 10.48 | 10.57 | 13.40 | 11.52 | 11.04 | 11.74 | 4.66 | 11.56 | 5.31 | 5.01 | 4.78 | 4.11 | 4.13 | |
| Profit before tax | -12.88 | -10.10 | -35.43 | -9.69 | -33.09 | -27.03 | 5.50 | -12.96 | -16.63 | -5.70 | 6.92 | 14.84 | 1.98 | |
| Tax % | -5.36% | 34.06% | -44.48% | 55.01% | -9.55% | -39.92% | -119.27% | -24.69% | -1.38% | 3.33% | -13.44% | -0.88% | 45.96% | |
| Net Profit | -12.19 | -13.54 | -19.67 | -15.02 | -29.93 | -16.24 | 12.06 | -9.76 | -16.40 | -5.89 | 7.85 | 14.97 | 1.07 | |
| EPS in Rs | -3.22 | -2.91 | -4.63 | -2.71 | -6.81 | -3.04 | 7.47 | -1.61 | -2.31 | 0.41 | 5.68 | 5.39 | 1.75 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202630.01%Promoter
Promoters30.01%
FIIs0.04%
Public69.95%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹451.70 | 68.55 | 18,223 | 0.28% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹657.65 | 37.17 | 15,854 | 0.34% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹269.40 | — | 7,637 | 0.00% | −107 | −38.33% | 1 | +30.43% | −79.54% |
| Vimta Labs | ₹467.65 | 25.70 | 2,094 | 0.43% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹140.37 | 20.99 | 625 | 0.43% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Take | ₹13.69 | 23.15 | 202 | 0.00% | 2 | +450.79% | 29 | — | 18.52% |
| Novelix Pharma. | ₹65.37 | 40.02 | 186 | 0.00% | 2 | +194.34% | 45 | +23.02% | 10.87% |
| Bilcare | ₹76.84 | 4.99 | 182 | 0.00% | 1 | +175.74% | 248 | +39.41% | 7.06% |
| Median: 9 Co. | ₹140.37 | 24.42 | 625 | 0.00% | 3 | +9.99% | 92 | +26.73% | 10.87% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Nov - Bilcare Limited the exchange about the Newspaper Publication of Un-Audited (Standalone and Consolidated) Financial Results for quarter and half ended 30 September 2026Results - Financial Results For September 30, 2026 3 Nov - Bilcare approved H1 FY27 results and appointed Mohan Bhandari Chairman effective 3 November 2026.Board Meeting Outcome for Outcome Of Board Meeting - Approval Of Standalone And Consolidated Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026, Along With Limited Review Reports And Change In Designation And Roles 3 Nov - Bilcare approved Q2/H1 FY26 results; Mohan Bhandari appointed chairman effective 3 Nov 2026.Board Meeting Intimation for For Un-Audited Financial Results For The Period Ended On 30 September 2026 27 Oct - Board meeting on 3 November 2026 to approve Q2 FY2026-27 standalone and consolidated results.Announcement Under Regulation 30(LODR) - Update On Voluntary Winding Up Of Bilcare INC US 19 Oct - Bilcare Inc US, a wholly owned non-material subsidiary, dissolved effective 9 September 2026.


